Clearmind Medicine

Clearmind Medicine (formerly Cyntar Ventures) is a psychedelic biotechnology company developing novel therapeutics based on 5-Methoxy-2-aminoindane (MEAI), a psychoactive compound, to treat common conditions that are not currently effectively being addressed such as binge drinking and alcohol abuse. 

Founded in 2017 as a mineral resource exploration company, the firm rebranded to “Clearmind Medicine” in May 2021 to shift its focus toward psychedelic therapies. In 2020, Clearmind hired Mr. Ezekiel Golan, a multidisciplinary inventor and discoverer of designer psychedelics, as a consultant and eventual Chief Scientific Officer and Director. Golan’s novel psychedelic analog, Molecule U, will be developed by ClearMind, to treat nicotine dependence and treatment-resistant depression. 

The company touts its intellectual property portfolio as a key strength, with 24 patents filed across the US, Europe, China, and India—nine of which have been granted. Further, since their collaboration in March 2022, Clearmind Medicine and SciSparc have submitted 13 patent applications, as of August 2024 , as part of a broader effort to develop novel psychedelic-derived therapeutics for under-treated mental health 

The company’s regulatory focus is obtaining FDA approval for its MEAI therapeutics that are believed to have promising efficacy and a high safety profile in preclinical studies. In July 2024 , it received Investigational New Drug approval from the FDA for its proprietary MEAI-based CMND-100 oral capsule, allowing the company to proceed with a Phase I/IIa clinical trial in the US. 

Clearmind Medicine was uplisted to the Nasdaq Capital Market from November 2022 , under the ticker symbol “CMND”.

Key customers and partnerships 

The company has entered several partnerships, including: 1) IMP Clinical Supply Services, to manage the global clinical supply chain for its drug candidate ( May 2023 ), 2) SciSparc and the Hebrew University of Jerusalem, to assess a combination treatment for obesity and metabolic syndrome ( June 2023 ), 3) CTS, to work on psychedelic-based product development ( August 2023 ), 4) Johns Hopkins University School of Medicine, for a Phase I/IIa clinical trial of CMND-100 ( September 2023 ), 5) BIRAD, to utilize their joint patent for a groundbreaking treatment for cocaine addiction ( February 2024 ), 6) Yissum Research Development Company at the Hebrew University of Jerusalem, to develop psychedelic compounds for PTSD and mental disorders ( April , May and August 2024).